Related references
Note: Only part of the references are listed.Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction
M. Rosenzweig et al.
BONE MARROW TRANSPLANTATION (2010)
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Bart Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
J. P. Laubach et al.
LEUKEMIA (2009)
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis
V. Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2007)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
G Palladini et al.
BLOOD (2005)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
DC Seldin et al.
BLOOD (2004)
Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis
A Fadia et al.
KIDNEY INTERNATIONAL (2003)
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis
DC Seldin et al.
CLINICAL LYMPHOMA (2003)
Share Paper
